Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zeposia

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Blue Latitude Health

Living my best life with multiple sclerosis

Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can...

Blue Latitude Health

- PMLiVE

Three key development areas in the management of multiple sclerosis

Last month, Mark Walker, our business development director, and Fabrice Allum, managing director of Porterhouse Insights, attended the ECTRIMS (European Committee for treatment and research in multiple sclerosis) congress in...

Porterhouse Medical Group

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise

Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients

Wilmington Healthcare

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Research Partnership

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links